Cargando…
BRCA1/2 testing: therapeutic implications for breast cancer management
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with breast cancer. Emerging breast and ovarian can...
Autores principales: | Tung, Nadine M., Garber, Judy E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048046/ https://www.ncbi.nlm.nih.gov/pubmed/29867226 http://dx.doi.org/10.1038/s41416-018-0127-5 |
Ejemplares similares
-
Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers
por: Song, Yun, et al.
Publicado: (2019) -
PARP inhibition in breast cancer: progress made and future hopes
por: Tung, Nadine, et al.
Publicado: (2022) -
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer
por: Tung, Nadine, et al.
Publicado: (2016) -
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
por: Friedman, Eitan, et al.
Publicado: (2006) -
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
por: Tung, Nadine, et al.
Publicado: (2010)